Clearside Biomedical’s Phase IIb ODYSSEY study of its drug-device combination CLS-AX (axitinib injectable suspension) has ...

The global AMD drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust ...

Age-related macular degeneration (AMD) is a leading cause of vision loss for adults over 50 in the United States. According ...

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024Topline clinical data from SOL-1 are now expected in Q4 2025BEDFORD, ...

For wet AMD, the goal of this treatment is to slow ... Anti-VEGF injections contain medications that treat abnormal and leaky blood vessels in your retina. The procedure is performed by a type ...

Clearside Biomedical today announced that the ODYSSEY study of its drug-device combination achieved its primary and secondary ...

Ocular Therapeutix's Elutyx drug delivery platform offers sustained long-term effects. See why OCUL stock is a Buy.

A common diabetes medication, metformin, might help treat a serious eye condition called age-related macular degeneration ...

D stock is a contrarian trade opportunity based on the market assumption that the promising Wet Amd eye disease gene therapy ...

ANX007 Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Photoreceptor Preservation in the Fovea ...

We recently published a list of Billionaire Ken Fisher’s 10 Favorite AI Stocks for the Rest of 2024. Since Advanced Micro ...

A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected ...